151 related articles for article (PubMed ID: 34119370)
21. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
22. Adenomatoid tumor of the adrenal gland: a report of four new cases and a review of the literature.
Raaf HN; Grant LD; Santoscoy C; Levin HS; Abdul-Karim FW
Mod Pathol; 1996 Nov; 9(11):1046-51. PubMed ID: 8933514
[TBL] [Abstract][Full Text] [Related]
23. TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma.
Itami H; Fujii T; Nakai T; Takeda M; Kishi Y; Taniguchi F; Terada C; Okada F; Nitta Y; Matsuoka M; Sasaki S; Sugimoto S; Uchiyama T; Morita K; Kasai T; Kawaguchi R; Ohbayashi C
Hum Pathol; 2021 May; 111():59-66. PubMed ID: 33667423
[TBL] [Abstract][Full Text] [Related]
24. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
Hwang HC; Pyott S; Rodriguez S; Cindric A; Carr A; Michelsen C; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815
[TBL] [Abstract][Full Text] [Related]
25. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
26. Mesothelial derived adenomatoid tumour in a location devoid of mesothelium: adrenal adenomatoid tumour.
Sağlıcan Y; Kurtulmus N; Tunca F; Süleyman E
BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26243749
[TBL] [Abstract][Full Text] [Related]
27. Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases.
Sangoi AR; McKenney JK; Schwartz EJ; Rouse RV; Longacre TA
Mod Pathol; 2009 Sep; 22(9):1228-35. PubMed ID: 19543245
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
30. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
31. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
32. Adenomatoid tumor of the adrenal gland.
Simpson PR
Arch Pathol Lab Med; 1990 Jul; 114(7):725-7. PubMed ID: 1694656
[TBL] [Abstract][Full Text] [Related]
33. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.
Sheffield BS; Hwang HC; Lee AF; Thompson K; Rodriguez S; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2015 Jul; 39(7):977-82. PubMed ID: 25634745
[TBL] [Abstract][Full Text] [Related]
34. Extragenital adenomatoid tumor of a mediastinal lymph node.
Isotalo PA; Nascimento AG; Trastek VF; Wold LE; Cheville JC
Mayo Clin Proc; 2003 Mar; 78(3):350-4. PubMed ID: 12630589
[TBL] [Abstract][Full Text] [Related]
35. Adenomatoid tumor of the adrenal gland: case report with immunohistochemical study.
Hamamatsu A; Arai T; Iwamoto M; Kato T; Sawabe M
Pathol Int; 2005 Oct; 55(10):665-9. PubMed ID: 16185299
[TBL] [Abstract][Full Text] [Related]
36. Adenomatoid of the adrenal gland.
Varkarakis IM; Mufarrij P; Studeman KD; Jarrett TW
Urology; 2005 Jan; 65(1):175. PubMed ID: 15667895
[TBL] [Abstract][Full Text] [Related]
37. Extragenital adenomatoid tumor: Evidence for the mesothelial theory of origin.
Craig JR; Hart WR
Cancer; 1979 May; 43(5):1678-81. PubMed ID: 156063
[TBL] [Abstract][Full Text] [Related]
38. Adenomatoid tumor of the mediastinum.
Goto M; Uchiyama M; Kuwabara K
Gen Thorac Cardiovasc Surg; 2016 Jan; 64(1):47-50. PubMed ID: 24839257
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
40. Oxyphilic adenomatoid tumor of the ovary: a case report with discussion of the differential diagnosis of ovarian tumors with vacuoles and related spaces.
Phillips V; McCluggage WG; Young RH
Int J Gynecol Pathol; 2007 Jan; 26(1):16-20. PubMed ID: 17197891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
